Top Markets
#1 Helium Helium +52.72%
#2 Seeker Seeker +50.59%
#3 Pons Pons +35.63%
#4 UnifAI Network UnifAI Network +31.30%
#5 Zylo Ecosystem Zylo Ecosystem +25.79%
#6 VVS Finance VVS Finance +24.87%
#7 TENDIES TENDIES +19.47%
#8 Bounce Bounce +17.09%
#9 Tensor Tensor +15.98%
#10 Songbird Songbird +15.53%
Coin of the day
Helium Helium
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Classement en actions #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Prix de l'action
$9.50
Dernière synchronisation: 2025-01-08
Capitalisation boursière
$819.52M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Poseida Therapeutics, Inc. (PSTX)

Catégorie

Healthcare
Bénéfices pour Poseida Therapeutics, Inc. (PSTX)
Bénéfices en Sep 2024 TTM : $-60.72M
Selon les derniers rapports financiers de Poseida Therapeutics, Inc., les bénéfices actuels de l'entreprise sont de $-60.72M. En 2022, l'entreprise a réalisé un bénéfice de $-63.46M, une diminution par rapport à celui de 2021 qui était de $-124.97K. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Poseida Therapeutics, Inc. de 2016 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
2026 (TTM) $-60.72M -50.77%
2023 $-123.32M 94.34%
2022 $-63.46M 50,676.96%
2021 $-124.97K -3.70%
2020 $-129.78K -99.85%
2019 $-86.53M 93.98%
2018 $-44.61M 120.94%
2017 $-20.19M 278.07%
2016 $-5.34M 0.00%
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -8,787.83%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -3,312.74%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 6,514.73%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 4,984.33%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH